




November 30, 2023  
JCR Pharmaceuticals Co., Ltd.

Translation

### **The Medal with Dark Blue Ribbon Awarded for Support Activities for “Momiji House,” a Medical Short-Term Facility for Children**

November 30, 2023 – [JCR Pharmaceuticals Co., Ltd.](https://www.jcr-pharm.com) (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced that it has received the Medal with Dark Blue Ribbon for its support activities for “Momiji House,” a medical short-term facility for children requiring medical care, operated by the National Center for Child Health and Development. The Medal with Dark Blue Ribbon is awarded by the Emperor to individuals, corporations, or organizations that have made exceptionally generous financial contributions for the good of the public.

Moreover, the award was sent to JCR today from Takashi Igarashi, M.D., Ph.D., President and Chief Executive Officer of the National Center for Child Health and Development.



From the left: Takashi Igarashi, M.D., Ph.D., President and Chief Executive Officer of the National Center for Child Health and Development and Shin Ashida, Chairman and President of JCR

“We are delighted to have continued stable operations of “Momiji House” up until now thanks to JCR’s support over many years.” said **Takashi Igarashi, M.D., Ph.D., President and Chief Executive Officer of the National Center for Child Health and Development.** “We make an effort to continue working to create a society where children who suffer from severe illness and disabilities requiring care at home, and their families, can enjoy a safe life.”

“One of the important missions for JCR is realizing medical care for patients and their families living with rare diseases.” said **Shin Ashida, Chairman and President of JCR.** “I hope that the circle of support will further expand and facilities like “Momiji House” will spread throughout Japan.”

JCR has continuously supported “Momiji House” since the project was first initiated in 2014, and will continue to endeavor to realize medical care for patients and their families living with rare diseases.

### **About “Momiji House,” a medical short-term facility for children**

“Momiji House” is Japan’s first medical short-term facility for children requiring medical care, built in April 2016 and located on the grounds of the National Center for Child Health and Development (Setagaya-ku, Tokyo). The facility provides full-time medical care for children who require constant medical care at home. Both children with severe illness and disabilities and their families can enjoy a safe and pleasant life together at “Momiji House,” these children’s second home. It is used by around 600 people per year.



**もみじの家**

Reference: Website of “Momiji House”, a medical short-term facility for children of the National Center for Child Health and Development

<https://home-from-home.jp/> (in Japanese)

### **About JCR Pharmaceuticals Co., Ltd.**

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS III A and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

#### Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jp.jcrpharm.com](mailto:ir-info@jp.jcrpharm.com)

###